【摘要】 目的探讨对ACS合并糖尿病患者在PCI后应用替格瑞洛和氯吡格雷进行抗血小板治疗的效果,并对患者预后情况进行分析。方法随机选取2016年10月—2018年6月于该院就诊的ACS合并糖尿病患者150例,在进行PCI后,将其随机分为A组与B组,A组患者应用替格瑞洛进行抗血小板治疗,B组患者应用氯吡格雷。结果 A组AA抑制率(64.63±16.34)%,高于B组(47.61±15.73)%;A组ADP抑制率(57.62±16.22)%,高于B组(31.45±14.63%);A组MA-ADP (33.89±17.43)%,低于B组(49.43±18.93)%,差异有统计学意义(t=6.499、10.376、5.230,P<0.05)。结论替格瑞洛对于ACS合并糖尿病的PCI术后患者抗血小板作用优于氯吡格雷,且不良事件更少。更多还原

【Abstract】 Objective To explore the effect of antiplatelet therapy with ticagrelor and clopidogrel after PCI in patients with ACS and diabetes, and to analyze the prognosis of patients. Methods Ramdomly selected 150 patients with ACS and diabetes who were treated in the hospital from October 2016 to June 2018 were randomly divided into group A and group B after PCI. Patients in group A were treated with ticagrelor for resistance Platelet therapy, clopidogrel was administered to patients in group B. Results The inhibition rate of AA in group A was(64.63 ± 16.34)%, which was higher than that of group B(47.61 ± 15.73)%; the inhibition rate of ADP in group A was(57.62 ± 16.22)%, which was higher than that of group B(31.45 ± 14.63)%; and the MA-ADP in group A was( 33.89 ± 17.43)%, which was lower than(49.43 ± 18.93)% of group B, and the differences were statistically significant(t =6.499, 10.376, 5.230, P <0.05). Conclusion Tigrelor has better antiplatelet effect and less adverse events in patients with ACS and diabetes after PCI.更多还原